This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The influenza vaccination was either a single dose or two doses and it was given to pregnant women during seasonal and pandemic influenza outbreaks.
Location/setting
USA/primary care.
Methods

Analytical approach:
The analysis used a stochastic computer simulation, which modelled the clinical and economic outcomes for both mothers and neonates, for a lifetime horizon. The authors stated that the perspectives of society and the third-party payer were adopted.
Effectiveness data:
The clinical data were from a selection of relevant studies and the criteria used to identify the most appropriate input from those available were not described. No information on the design or other characteristics of the selected sources was provided. The vaccine efficacy was the key clinical input to the model.
Monetary benefit and utility valuations:
The utility values were from published sources and their details were not reported.
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure.
Cost data:
The economic analysis considered costs, for both mothers and neonates, of: death, home treatment of influenza, home treatment of vaccine-related adverse effects, hospitalisations for influenza, vaccine acquisition and administration, preterm birth, and productivity losses for out-patient visits due to illness. These costs and quantities were from published sources, but their details were not reported. All costs were in US dollars ($) and the price year was 2009. Future costs were discounted at an annual rate of 3%.
Results
From the societal perspective, the incremental cost per QALY gained with single-dose vaccination over no immunisation ranged from dominant, which meant that vaccination was cheaper and more effective, to cost-effective, which was below the threshold of $50,000 per QALY, in all scenarios, regardless of the severity of the influenza strain, as long as the prevalence of influenza was over 2.5%. From the perspective of the third-party payer, single-dose vaccination was the preferred strategy (below the established threshold) when the prevalence of influenza was 2.5% or more and the probability of influenza-attributable mortality was equal to or greater than the expected seasonal rate.
From the societal perspective, the two-dose vaccination was cost-effective, but not dominant, over no vaccination when the influenza prevalence was 7.5% or more, for all scenarios. It was also cost-effective when the prevalence of influenza was 5% or more and the mortality due to influenza was three or four times the expected seasonal-influenza mortality.
Variations in the vaccine efficacy did not substantially change these findings. The most influential model inputs were the influenza prevalence and severity of illness. The probabilistic analysis showed that when influenza prevalence was set at 12.5% and the societal willingness to pay for a QALY was $50,000, the probability of vaccination being costeffective was around 90%. At higher prevalence rates the probability of vaccination being cost-effective increased.
